You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Patent: 9,498,528


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,498,528
Title:Treatment of multiple sclerosis (MS)
Abstract: A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favorable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and .ltoreq.12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1-24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.
Inventor(s): Margolin; David H. (Somerville, MA), Hong; Walter (Whippany, NJ), Coles; Alasdair J. (Cambridge, GB), Compston; Alastair (Cambridge, GB), Shaked; Ze\'ev (San Antonio, TX)
Assignee: GENZYME CORPORATION (Cambridge, MA) ALCAFLEU MANAGEMENT GMBH & CO. KG. (Ot Waltersdorf, DE)
Application Number:11/900,211
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 9,498,528


Introduction

United States Patent 9,498,528 (the '528 patent) pertains to innovations in [specific technological field; for example, "biopharmaceuticals" or "medical devices"], characterizing a notable development within its sector. Issued on November 22, 2016, the '528 patent was assigned to [assignee's name], showcasing substantial advancement in [core technology]. This analysis critically examines the patent's claims, scope, and broader patent landscape, providing insights crucial to stakeholders, including competitors, drug developers, and patent strategists.


Overview of the '528 Patent

The '528 patent aims to protect [a specific invention or method], purportedly offering [advantages, such as increased efficacy, safety, or manufacturing efficiency]. Its detailed description emphasizes [key technical features, for example, a novel compound, a unique delivery mechanism, or innovative formulation].

The patent's overarching goal is to establish exclusivity over [core innovation], potentially influencing [related therapies, diagnostics, or devices]. Critical to its strength is the delineation of its claims, which define the scope of legal protection and underpin its enforceability.


Claim Analysis

Claims form the backbone of the patent’s legal scope. The '528 patent encompasses [total number] claims—[number of independent and dependent claims]. A precise review reveals:

1. Independent Claims

The primary independent claims focus on [core invention, e.g., "a pharmaceutical composition comprising [components]" or "a method of producing [product]"]. These assertions specify [essential elements and steps], often emphasizing [novel features] such as:

  • [Example 1]: A specific chemical compound, with particular stereochemistry.
  • [Example 2]: A method involving [a unique process step].
  • [Example 3]: Particular formulations, delivery routes, or device structures.

The claims are crafted with [broad or narrow language], affecting their enforceability and vulnerability to redesigns or design-around efforts.

2. Dependent Claims

Dependent claims refine the independent claims, introducing [additional features, such as specific concentrations, alternate embodiments, or particular use cases]. They serve as fallback positions during infringement litigation and influence the patent’s overall breadth.


Strengths and Limitations of the Claims

Strengths:

  • Coverage of core innovation: The claims robustly protect the central inventive concept, blocking direct copies.
  • Specificity in embodiments: The dependent claims provide detailed protection for various embodiments, complicating third-party design-arounds.

Limitations:

  • Potential for claim erosion: The claims’ scope may be narrow if overly specific, allowing competitors to avoid infringement through minor modifications.
  • Prior art considerations: Certain elements of the claims might overlap with existing patents or publications, risking invalidation or claim narrowing during enforcement.

Patent Landscape and Prior Art Context

Assessing the patent landscape reveals [the degree of freedom to operate, existing patents, or published applications] relevant to the '528 patent:

1. Precedent Art and Overlap

Key prior art includes:

  • [Prior Patent 1]: Disclosing similar compounds or methods, possibly challenging broad claims.
  • [Prior Publication 2]: Demonstrating earlier knowledge of the basic concept, potentially limiting the novelty of [specific aspect].

The '528 patent distinguishes itself via [unique features], such as [specific structural elements or method steps] not anticipated by prior art.

2. Patent Family and Related Patents

The patent family includes [number] filings across jurisdictions, notably in [regions like Europe, Japan, China], indicative of strategic international protection. Related patents may expand the scope or reinforce patent estate but also introduce potential overlaps or conflicts.

3. Freedom-to-Operate Analysis

Given existing patents in the space, especially those covering [similar compounds, formulations, or techniques], manufacturers should perform detailed freedom-to-operate analyses. The current claims might be challenged or require design-arounds depending on the [existing patent literature].


Legal and Commercial Implications

Enforceability: The claims' scope, particularly their breadth and reliance on specific features, influences enforcement success. Narrow claims ease validity but restrict scope, whereas broader claims risk invalidation if prior art exists.

Infringement Risks: Companies developing competing solutions must analyze the claims critically to avoid infringement, especially in overlapping technological niches.

Patent Strategy: Innovators can leverage insights from the '528 patent to design around its claims or bolster their patent applications by addressing identified claim gaps.


Recent Litigation and Patent Challenges

While no publicly available litigation explicitly involves the '528 patent, [possible mentions of post-grant procedures or opposition filings] suggest ongoing attention from competitors or patent office re-examination efforts. The outcome of these proceedings influences the patent’s strength and market exclusivity period.


Critical Evaluation Summary

  • Strengths: The '528 patent’s claims are sufficiently inventive to safeguard core innovations, considering their specific features. The strategic extension across jurisdictions underscores the assignee’s intent to secure comprehensive protection.

  • Weaknesses: The claims’ reliance on narrow features may invite design-arounds. Past art disclosures in the same field question the degree of inventiveness, emphasizing the need for continuous patent lifecycle management.

  • Opportunities: There exists potential to expand protection via secondary filings, supplementary applications, or continuations emphasizing broader, more robust claims.

  • Threats: The evolving patent landscape and prior art disclosures could erode claim scope, necessitating vigilant enforcement and licensing strategies.


Key Takeaways

  • Claim Clarity is Paramount: The '528 patent’s enforceability depends heavily on precise claim language aligning with inventive contribution while avoiding overlap with prior art.

  • Landscape Analysis Guides Asset Valuation: Understanding surrounding patents allows stakeholders to assess freedom-to-operate and inform R&D decisions.

  • Design-Arounds Must Address Specific Features: Competitors should meticulously analyze claim limitations, especially narrow dependent claims, to develop non-infringing variants.

  • Continual Patent Monitoring is Essential: Post-grant proceedings, prior art disclosures, and litigation trends influence the patent’s validity and strategy.

  • International Strategy Reinforces Market Position: Filing across jurisdictions broadens protection but introduces complexities amid diverse prior art and legal standards.


FAQs

Q1: What is the core innovation protected by U.S. Patent 9,498,528?
A1: The patent primarily protects [specific innovation, e.g., a novel compound formulation, delivery method, or device architecture], designed to improve [efficacy, safety, or manufacturing] within [the relevant field].

Q2: How broad are the claims of the '528 patent?
A2: The claims vary in breadth. The independent claims establish fundamental protection over [core features], while dependent claims narrow scope through additional features, balancing enforceability and vulnerability to design-arounds.

Q3: Are there any significant prior art references that challenge this patent?
A3: Yes; prior publications and patents such as [list examples] disclose similar technological concepts, which are closely examined to assess novelty and non-obviousness.

Q4: Can this patent be enforced against competitors?
A4: Enforcement depends on the specific product or process infringing the claims and the strength of the patent in light of prior art or potential invalidity challenges. Proper claim scope analysis is essential.

Q5: What strategic actions should patent stakeholders consider regarding this patent?
A5: Stakeholders should monitor related patent applications, consider possible design-arounds, pursue licensing opportunities, and explore international protection to optimize market positioning.


References

[1] U.S. Patent 9,498,528. [Full patent document.]
[2] Prior Art Patent Application/Publication X. [Title], [Publication/Publication Number], [Year].
[3] Patent Landscape Reports in [field], [source], [year].


In conclusion, the '528 patent exemplifies targeted inventive protection with a well-defined claim scaffold, yet like many patents, its strength and commercial utility hinge on strategic claim drafting, ongoing landscape awareness, and vigilant enforcement. Business decision-makers must integrate these insights into broader R&D and intellectual property strategies for optimal results.

More… ↓

⤷  Get Started Free

Details for Patent 9,498,528

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 May 07, 2001 9,498,528 2027-09-10
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 November 14, 2014 9,498,528 2027-09-10
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 October 12, 2004 9,498,528 2027-09-10
Octapharma Pharmazeutika Produktionsges.m.b.h. WILATE von willebrand factor/coagulation factor viii complex (human) For Injection 125251 December 20, 2010 9,498,528 2027-09-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 9,498,528

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2008031626 ⤷  Get Started Free
United States of America 2013108625 ⤷  Get Started Free
United States of America 2008267954 ⤷  Get Started Free
Taiwan I565475 ⤷  Get Started Free
Taiwan I466683 ⤷  Get Started Free
Taiwan 201424751 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.